What AI Gets Wrong About Pediatric Drug Use — and Why Pharma Brands Must Monitor It Now
A parent in Texas asks ChatGPT how much ibuprofen to give her 18-month-old. ChatGPT returns a dose calculated for a […]
ChatGPT Is Now Where Patients Learn About Drugs: What Pharma Must Do Before the FDA Does It for Them
The shift happened without a product launch, without a press release, and without a single pharmaceutical company authorizing it. Sometime
AI Visibility Is Now a Pharma Compliance Issue. Here’s the Proof.
Walk into any pharmaceutical compliance team’s weekly meeting and you’ll find the same agenda items from the past decade: OPDP
How Drug Brands Stopped Off-Label Use and Stayed on the Market
How drug brands fought off-label prescribing to survive: real FDA cases, litigation wins, and what AI monitoring means for pharmacovigilance
The Drugs Athletes Actually Worry About
If you spend enough time around athletes, weekend warriors, or anyone optimizing “fitness,” you start to notice a recurring theme:
The $150 Billion Side Hustle Happening Inside Medicine Cabinets
Why migraine drugs became weight-loss forums, cholesterol pills turned into food-interaction experiments, and cancer therapies spawned Reddit-scale crowdsourced medicine. There’s
AI Pharmacovigilance: How Drug Companies Track Safety Signals in Real Time | DrugChatter
AI Pharmacovigilance: How Drug Companies Track Safety Signals Before Regulators Do The FDA receives roughly 2 million adverse event reports
AI Is Eating Drug Information. Here’s What Pharma Must Do Before a Patient Acts on It.
Chatbots now answer drug questions that once required a detail rep, a pharmacist, or a Medical Information call center. The
The Vioxx Collapse: What Off-Label Sales Tactics Teach Pharma About AI Monitoring Today
On September 30, 2004, Merck pulled Vioxx from every pharmacy shelf in the world. The withdrawal took less than 24
The Drug Isn’t Gone — But It Might As Well Be: What Patients Really Ask When Supply Gets Weird
If you want to understand drug shortages, don’t start with FDA dashboards. Start with patient questions. They don’t say “supply
How AI Is Rewriting Drug Commercialization — Before Regulators Catch Up
A look at the $50B opportunity reshaping how pharma companies launch, monitor, and defend their brands in the age of
When AI Rewrites the Label: The Prescribing Risk Pharma Can’t Afford to Ignore
Physicians are increasingly asking AI chatbots how to dose drugs, manage contraindications, and choose between therapies. The AI answers. The
